X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/alkermes-announces-initiation-of-vibrance-1-phase-2-study-evaluating-alks-2680-for-the-treatment-of-narcolepsy-type-1-302125993.html
https://www.prnewswire.com/news-releases/alkermes-to-report-first-quarter-financial-results-on-may-1-2024-302119806.html
https://www.prnewswire.com/news-releases/alkermes-announces-positive-topline-results-from-phase-1b-study-of-alks-2680-demonstrating-improved-wakefulness-in-patients-with-narcolepsy-type-2-and-idiopathic-hypersomnia-302111041.html
https://www.prnewswire.com/news-releases/alkermes-presents-analyses-from-long-term-safety-study-of-lybalvi-olanzapine-and-samidorphan-at-2024-congress-of-the-schizophrenia-international-research-society-302109802.html
https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-appointment-nancy-s-lurker-board-directors
https://www.prnewswire.com/news-releases/alkermes-plc-reports-financial-results-for-the-fourth-quarter-and-year-ended-dec-31-2023-and-provides-financial-expectations-for-2024-302062983.html
https://www.fiercepharma.com/pharma/good-news-lybalvi-alkermes-sees-10-stock-price-increase
https://investor.alkermes.com/news-releases/news-release-details/alkermes-report-fourth-quarter-and-year-end-financial-results-0
https://www.fiercepharma.com/pharma/jpm24-after-transformational-year-alkermes-moves-pure-play-neuroscience-specialist
https://www.prnewswire.com/news-releases/alkermes-announces-topline-results-from-long-term-open-label-safety-and-durability-of-treatment-effect-study-of-lybalvi-olanzapine-and-samidorphan-302024987.html
Market Place
Share 
